GlobeNewsWire
05 Jan 2026, 12:30 UTC · 36w ago
Verdict
Headline takes no side. We score CRBP +0.60 across three claims — strongly bullish.
+0.60strongly bullish
More positive than 76% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Corbus Pharmaceuticals received FDA clearance to proceed with the TEMPO-1 registrational study of CRB-701 for second-line oropharyngeal cancer.
More positive than 92% of claims this week
The company expects to initiate enrollment for the TEMPO-1 study in September 2026.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 55% of claims this week
CEO Yuval Cohen will present a corporate overview at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026.
More positive than 47% of claims this week
Which stocks this story touches
More positive than 76% of ticker scores this week
The company is presenting at a major healthcare conference and has obtained FDA clearance to proceed with a registrational study for CRB-701.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
1d ago
+2.7%
Price agrees with the score
$8.08 vs $7.87 close before publication (Jan 2) · not market-adjusted
CRBP chart →
